Lili Yang lab licenses cell-therapy tech to start-up, receives CIRM TRAN1 award, and publishes two papers in Science Immunology and Nature Communications. 

June 16th, 2021

The Yang lab recently published two papers back-in-back on Science Immunology and Nature Communications, reporting the identification of a new immune checkpoint and the repurposing of an old antidepressant for cancer immunotherapy. Details HERE and HERE.

The Yang lab also received CIRM TRAN1 award worth $5.9 million supporting the development of an off-the-shelf CAR-iNKT cell therapy for multiple myeloma. Read more HERE.

Additionally, the Yang lab’s off-the-shelf cell therapy technology was licensed by a biotech startup, Appia Bio, for commercial development. The company recently launched with $52 million Series A financing. You can read more about the licensing agreement HERE.

Timothy O’Sullivan receives Excellence in Research Award

June 7th, 2021

Excellence in Research Award for an Untenured Professor
Timothy O’Sullivan – Assistant Professor, Microbiology, Immunology, & Molecular Genetics
Dr. O’Sullivan is awarded for his paper, “ILC1 Confer Early Host Protection at Initial Sites of Viral Infection” Cell 2017. In this impressive paper, Dr. O’Sullivan and colleagues show that a unique subset of immune cells within tissues represents the first line of defense to viral infections. Without this rapid tissue-resident immune cell response, the immune system cannot efficiently control viral replication resulting in more severe infections.

New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin’s B-cell lymphoma

April 16, 2021

New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin’s B-cell lymphoma. MIMG’s Dr. Yvonne Chen involved in developing the engineered CARs. More info HERE.

MIMG Undergraduate spotlighted for recently published researched papers

March 30, 2021

Read about Roni Touboul on the Undergraduate Research Center website HERE.